ANDA 208357, held by Novast Labs. Desmopressin Acetate.
As of Nov 16, 2026, ANDA 208357 (Desmopressin Acetate), held by Novast Labs, was first approved by FDA on Jun 6, 2019, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jun 6, 2019 | Original application | Approved | None posted |
| Desmopressin Acetate0.1MG · tablet;oral | Desmopressin Acetate | Rx |
| Desmopressin Acetate0.2MG · tablet;oral | Desmopressin Acetate | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters